Galapagos delivers candidate drug in GSK alliance, receives â‚¬6.7 million
Mechelen, Belgium; 2 March 2011 - Galapagos NV (Euronext: GLPG) announced today
that it delivered a fourth candidate drug in its arthritis alliance with
GlaxoSmithKline (GSK) in December 2010. Â This achievement triggered a â‚¬6.7
million milestone payment to Galapagos, which was included in 2010 revenues.
This latest pre-clinical candidate is a small molecule that meets the chemical
and biological criteria set by GSK for a potential new medicine. Â Galapagos will
now start scale-up chemistry and comprehensive safety evaluation, with the aim
to initiate Phase I clinical trials in early 2012.
"The arthritis alliance with GSK has been very fruitful in delivering promising
candidate drugs," said Onno van de Stolpe, CEO of Galapagos. Â "In this alliance,
we currently have two clinical trials, with plans to progress this new candidate
into the clinic next year."
About Galapagos' arthritis alliance with GlaxoSmithKline
GSK and Galapagos initiated an arthritis alliance to discover and develop
disease-modifying drugs for GSK's global R&D organization in June 2006.Â GSK and
Galapagos expanded the alliance on three occasions to include additional targets
and increase the number of programs.Â Following the latest expansion in December
2009, Galapagos is eligible to receive more than â‚¬200 million in milestones,
plus up to double-digit royalties from GSK.Â GSK has an exclusive option to
further develop and commercialize these compounds on a worldwide basis.Â Since
the start of the arthritis alliance, Galapagos has received more than â‚¬60
million in payments from GSK.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action.Â The Company is progressing one of the
largest pipelines in biotech, with seven clinical and over 50 discovery
programs.Â Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly,
Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to receive up to
â‚¬2.5 billion in downstream milestones, plus royalties.Â The Galapagos Group has
over 800 employees and operates facilities in seven countries, with global
headquarters in Mechelen, Belgium.Â More info at: www.glpg.com
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Â Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. Â These forward-looking statements speak only as
of the date of publication of this document. Â Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE